iRhythm Technologies stock (US4627231087): Governance vote, Nasdaq trading in focus

iRhythm Technologies is in focus after shareholders approved a new equity incentive plan and board-related items at the annual meeting on 05/27/2026. The stock remains listed on Nasdaq in the United States, with no new earnings release in the latest session.

iRhythm Technologies drew fresh attention after investors approved a new 2026 Equity Incentive Plan, elected all nine director nominees, and ratified KPMG as auditor at the annual meeting held on 05/27/2026, according to a company filing. The shares continue to trade on Nasdaq in the United States under IRTC, which keeps the home-country angle centered on U.S. governance and listing activity.

The stock was also referenced in a MarketWatch/Morningstar wearables roundup on 05/28/2026, which noted iRhythm Technologies among companies developing medical-grade wearables, adding a broader sector backdrop to the latest U.S. trading narrative.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: iRhythm Technologies
• Sector/industry: Medical technology
• Headquarters/country: San Francisco, United States
• Core markets: United States, with additional international commercialization
• Key revenue drivers: Zio cardiac monitoring systems and related service revenue
• Home exchange/listing venue: Nasdaq (IRTC)
• Trading currency: USD

iRhythm Technologies: core business model

iRhythm Technologies develops and commercializes medical-grade wearable cardiac monitoring systems that help detect and analyze heart rhythm conditions, with revenue mainly tied to its Zio platform and associated services.

Recent corporate actions

The company said stockholders approved an amended and restated certificate of incorporation that removes the pass-through voting provision, which makes governance changes the main fresh corporate action disclosed in the latest filing.

This matters because the filing was dated 05/27/2026 and followed the annual meeting rather than a financial release, so the near-term story is centered on corporate structure and shareholder voting rather than guidance or quarterly performance.

Valuation metrics and multiples for iRhythm Technologies

According to TipRanks on 05/29/2026, the most recent analyst rating shown for iRhythm Technologies was a Buy with a $180.00 price target, giving readers a current market snapshot from a U.S.-focused research aggregator.

That consensus-style data point is useful for context, but it does not replace company-reported fundamentals, and no fresh earnings or valuation release was identified in the sources used for this article.

Conclusion

The latest catalyst is governance, not earnings, with the annual meeting filing giving the stock its clearest same-day trigger. For Friday's valuation lens, the key reference point is the Buy rating and $180.00 target highlighted by TipRanks as of 05/29/2026, while the Nasdaq listing keeps the U.S. market context in view.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.